Ipsen and Tercica to Enter into Worldwide Strategic Collaboration in Endocrinology (Canada News Wire, July 18 2006)

Ipsen and Tercica today announced that they have agreed to a worldwide strategic collaboration in endocrinology. In cross licensing agreements, Ipsen will grant to Tercica exclusive rights to sell(1) Somatuline(R) Autogel(R), a leading product in the European acromegaly market, in the United States and Canada. Tercica will grant to Ipsen exclusive rights to sell Increlex(TM), a leading product in the United States for the treatment of short stature associated with severe Primary IGF-1 deficiency (Primary IGFD), in all regions of the world except the United States, Japan, Canada, the Middle East and Taiwan.

Full article